Metaxin® modulates Epithelial-Mesenchymal Transition (EMT), whereas tumour cells loose adhesion to the primary tumor and extracellular matrix (ECM) promoted by proteolytic degradation of the ECM by enzymes like matrix metalloproteinases (MMPs); and the activation of signaling pathways that promote cell motility and survival. Broadly, Metaxin® has two mechanisms of action.
Metaxin® inhibits MMP-3 and MMP-9 and secondly, promotes the activation of tumor-associated-macrophages (M1-type) within the cancerous tissues through increased Interferon-gamma (IFN-γ) production within the tumour micro-environment. Additionally, Metaxin® contains complex blend of flavonoids which inhibit PD/PDL1 interaction, thus, reactivates the body's immune system to attack cancer cells.
MyoFibrox® is a polyherbal formulation exhibiting combinatorial mechanism of action aimed at reducing uterine size. First, MyoFibrox ® weakly inhibits nuclear receptor subfamily 3, group C, member 3 (progesterone receptor) and estrogen receptor (ER).
Prostafexin® is a polyherbal formulation exhibiting combinatorial mechanism of action aimed at reducing prostate size. First, Prostafexin® specifically inhibits prostate 5α-reductase type 2.
Atxilox® is a polyherbal formulation exhibiting varying mechanism of action. First, Atxilox® inhibits The Mammalian Target of Rapamycin (mTOR) kinase.
